Assenagon Asset Management S.A. Trims Stock Position in AngioDynamics, Inc. $ANGO

Assenagon Asset Management S.A. trimmed its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 88.3% during the first quarter, Holdings Channel reports. The institutional investor owned 27,727 shares of the medical instruments supplier’s stock after selling 209,353 shares during the period. Assenagon Asset Management S.A.’s holdings in AngioDynamics were worth $315,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ANGO. SG Americas Securities LLC increased its stake in shares of AngioDynamics by 24.1% during the 1st quarter. SG Americas Securities LLC now owns 37,158 shares of the medical instruments supplier’s stock valued at $422,000 after acquiring an additional 7,220 shares during the last quarter. Hsbc Holdings PLC grew its holdings in AngioDynamics by 128.4% in the fourth quarter. Hsbc Holdings PLC now owns 62,367 shares of the medical instruments supplier’s stock valued at $801,000 after purchasing an additional 35,062 shares during the period. Mercer Global Advisors Inc. ADV grew its holdings in AngioDynamics by 38.1% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 14,604 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 4,030 shares during the period. XTX Topco Ltd increased its position in AngioDynamics by 69.6% during the fourth quarter. XTX Topco Ltd now owns 40,811 shares of the medical instruments supplier’s stock worth $524,000 after purchasing an additional 16,742 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new position in AngioDynamics during the fourth quarter worth approximately $463,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Analysts Set New Price Targets

ANGO has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. Zacks Research downgraded AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. Freedom Capital raised AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. Finally, Canaccord Genuity Group reduced their target price on AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.67.

AngioDynamics Price Performance

NASDAQ ANGO opened at $13.09 on Friday. AngioDynamics, Inc. has a fifty-two week low of $8.36 and a fifty-two week high of $13.99. The business has a 50 day moving average price of $11.80 and a two-hundred day moving average price of $11.36. The stock has a market cap of $540.88 million, a PE ratio of -17.45 and a beta of 0.34.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. The company had revenue of $78.42 million for the quarter, compared to analyst estimates of $76.77 million. Sell-side analysts anticipate that AngioDynamics, Inc. will post -0.19 EPS for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.